Comanche Biopharma is developing novel siRNA (Small interfering RNA) compounds to treat preeclampsia via gene silencing.
The protein sFLT-1 is believed to be the cause of preeclampsia. This protein, produced by the placenta and measurable in the plasma of pregnant women, is both diagnostic and prognostic for preeclampsia and is causally responsible for its disease manifestations when over-expressed.
Comanche Biopharma is developing conjugated siRNA compounds that accumulate in the placenta where they selectively down-regulate multiple mRNA isoforms coding for sFLT-1 while leaving important angiogenic factors unaffected. By specifically and durably silencing the sFLT-1 gene in the placenta they are able halt production of the protein responsible for preeclampsia.
According to the company, the burden of preeclampsia is substantial and growing in frequency and severity. It results in 10 million patients worldwide with more than 500,000 infant and nearly 80,000 maternal deaths every year.
Subscribe for alerts on new companies featured on Startups.Bio
U-Ploid Biotechnologies aims to revolutionize IVF for Age-Related Infertility. Millions of women around the world face the emotional and financial toll of age-related infertility. As …
BioTryp Therapeutics is University of Cambridge spin-out biotechnology company that focuses on the development of small molecules to inhibit biofilm formation, which causes 80% of …
Bastion Therapeutics is a pre-clinical stage biotechnology company focused on developing best-in-class Treg cell therapies, which can target the root causes of inflammatory disorders and …
HOVANA is a digital biology company tackling translational dysfunction as a driver of serious diseases. Leveraging insights into cellular reprogramming, HOVANA is inventing a new …
Founded in 2022, Couragene is a biotechnology company developing first-in-class in vivo genetic therapies using its proprietary delivery platforms. The company's technology holds potential for …
Function Oncology is a precision medicine company advancing a CRISPR-powered personalized functional genomics platform to understand cancer in unprecedented and patient-specific detail. By moving beyond …
